-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] In recent years, under the background of the country's vigorous promotion of pharmaceutical innovation, more and more pharmaceutical companies have begun to focus on innovative research and development, and this has also brought new growth points to their own performanc.
Innovative drugs are helping a large number of pharmaceutical companies usher in new performance! (Source: Pharmaceutical Network) Recently, Simcere Pharmaceuticals released its semi-annual report showing that as of June 30, 2022, the group expects to earn approximately RMB 67 billion to RMB 73 billion in revenue, an increase of approximately 26% compared to RMB 12 billion in the same period last yea.
29.
It is worth mentioning that the expected growth is mainly attributable to the rapid increase in the sales of innovative drug.
According to public information, the Group's innovative drug revenue in 2021 will reach approximately RMB 12 billion, an increase of 58% over the same period last year, and the proportion of innovative drug revenue has reached a record high of 64.
Among them, Xianbixin will achieve revenue of 543 billion yuan in 2021, driving the nervous system business to increase by 113% year-on-yea.
The industry expects that with the continuous acceleration of new drug development and launch of Simcere Pharma, its innovative drug revenue may usher in a new wave of growt.
It is understood that Simcere currently has nearly 60 innovative drug R&D pipelines and 19 innovative drugs in the clinical stag.
With the continuous increase in R&D investment, its clinical development and registration work is still advancing rapidl.
In addition to Simcere Pharmaceuticals, Innovent has also established a product chain including 32 new drug varieties, covering tumor, autoimmunity, metabolism, ophthalmology and other disease area.
As of the end of the second quarter of 2022, 7 of these products have been commercialized, and the total product revenue has exceeded 1 billion yua.
There is also Hengrui Medicin.
In the first half of 2021, the sales revenue of innovative drugs has reached 207 billion yuan, accounting for about 40% of the overall revenu.
On the whole, many innovative drug companies are ushering in more benefits with innovative product.
The industry expects that with the approval of more new drugs in the future, the performance of a large number of pharmaceutical companies will usher in a new wave of growt.
However, it should be noted that at the same time, pharmaceutical companies will continue to increase their innovation and R&D effort.
It is understood that the R&D investment of Zhongsheng Pharmaceutical in the first half of the year reached 84389 million yuan, a year-on-year increase of 225.
Yunnan Baiyao intends to increase R&D investment in recent year.
From 2017 to 2021, the company's R&D investment is also increasing, with 84 million yuan, 110 million yuan, 174 million yuan, 181 million yuan, and 331 million yuan respectivel.
In addition, Jichuan Pharmaceutical's research and development expenses in 2021 have reached 523 million yuan, accounting for 86% of revenu.
In the same year, the cumulative R&D investment of Hengrui Medicine also reached 203 billion yuan, a year-on-year increase of 234%, a record hig.
It is reported that its net profit that year was 53 billion yuan, which means that Hengrui Medicine's R&D investment in that year has far exceeded the net profit of that yea.
Behind the increasing investment in research and development by pharmaceutical companies, it can be seen that innovation has become an urgent issue for most pharmaceutical companie.
Although the current pharmaceutical innovation is still difficult and the process is full of uncertainties, the industry believes that as the State Food and Drug Administration continues to issue favorable documents to promote the registration and listing of new drugs, it will continue to encourage pharmaceutical companies to innovate more activel.
In the future, innovative drugs will also bring new performance growth to more companie.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
Innovative drugs are helping a large number of pharmaceutical companies usher in new performance! (Source: Pharmaceutical Network) Recently, Simcere Pharmaceuticals released its semi-annual report showing that as of June 30, 2022, the group expects to earn approximately RMB 67 billion to RMB 73 billion in revenue, an increase of approximately 26% compared to RMB 12 billion in the same period last yea.
29.
It is worth mentioning that the expected growth is mainly attributable to the rapid increase in the sales of innovative drug.
According to public information, the Group's innovative drug revenue in 2021 will reach approximately RMB 12 billion, an increase of 58% over the same period last year, and the proportion of innovative drug revenue has reached a record high of 64.
Among them, Xianbixin will achieve revenue of 543 billion yuan in 2021, driving the nervous system business to increase by 113% year-on-yea.
The industry expects that with the continuous acceleration of new drug development and launch of Simcere Pharma, its innovative drug revenue may usher in a new wave of growt.
It is understood that Simcere currently has nearly 60 innovative drug R&D pipelines and 19 innovative drugs in the clinical stag.
With the continuous increase in R&D investment, its clinical development and registration work is still advancing rapidl.
In addition to Simcere Pharmaceuticals, Innovent has also established a product chain including 32 new drug varieties, covering tumor, autoimmunity, metabolism, ophthalmology and other disease area.
As of the end of the second quarter of 2022, 7 of these products have been commercialized, and the total product revenue has exceeded 1 billion yua.
There is also Hengrui Medicin.
In the first half of 2021, the sales revenue of innovative drugs has reached 207 billion yuan, accounting for about 40% of the overall revenu.
On the whole, many innovative drug companies are ushering in more benefits with innovative product.
The industry expects that with the approval of more new drugs in the future, the performance of a large number of pharmaceutical companies will usher in a new wave of growt.
However, it should be noted that at the same time, pharmaceutical companies will continue to increase their innovation and R&D effort.
It is understood that the R&D investment of Zhongsheng Pharmaceutical in the first half of the year reached 84389 million yuan, a year-on-year increase of 225.
Yunnan Baiyao intends to increase R&D investment in recent year.
From 2017 to 2021, the company's R&D investment is also increasing, with 84 million yuan, 110 million yuan, 174 million yuan, 181 million yuan, and 331 million yuan respectivel.
In addition, Jichuan Pharmaceutical's research and development expenses in 2021 have reached 523 million yuan, accounting for 86% of revenu.
In the same year, the cumulative R&D investment of Hengrui Medicine also reached 203 billion yuan, a year-on-year increase of 234%, a record hig.
It is reported that its net profit that year was 53 billion yuan, which means that Hengrui Medicine's R&D investment in that year has far exceeded the net profit of that yea.
Behind the increasing investment in research and development by pharmaceutical companies, it can be seen that innovation has become an urgent issue for most pharmaceutical companie.
Although the current pharmaceutical innovation is still difficult and the process is full of uncertainties, the industry believes that as the State Food and Drug Administration continues to issue favorable documents to promote the registration and listing of new drugs, it will continue to encourage pharmaceutical companies to innovate more activel.
In the future, innovative drugs will also bring new performance growth to more companie.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
